Competing Risk Analysis of the Impact of Pedal Arch Status and Angiosome-Targeted Revascularization in Chronic Limb-Threatening Ischemia
- PMID: 32278873
- DOI: 10.1016/j.avsg.2020.03.042
Competing Risk Analysis of the Impact of Pedal Arch Status and Angiosome-Targeted Revascularization in Chronic Limb-Threatening Ischemia
Abstract
Background: In the context of chronic limb-threatening ischemia, the prognostic impact of angiosome-targeted revascularization and of the status of the pedal arch are debated.
Methods: This series includes 580 patients who underwent endovascular (n = 407) and surgical revascularization (n = 173) of the infrapopliteal arteries for chronic limb-threatening ischemia associated with foot ulcer or gangrene. The risk of major amputation after infrapopliteal revascularization was assessed by a competing risk approach. A subanalysis was made separately for patients who underwent endovascular or open surgical revascularization.
Results: At 2 years, survival was 65.1% and leg salvage was 76.1%. Multivariable competing risk analysis showed that C-reactive protein ≥10 mg/dL, diabetes, rheumatoid arthritis, increased number of affected angiosomes, and the incomplete or total absence of pedal arch compared with complete pedal arch (CPA) were independent predictors of major amputation after infrapopliteal revascularization. Multivariable analysis showed increasing risk estimates of major amputation in patients with incomplete (subdistribution hazard ratio [SHR], 2.131; 95% confidence interval [95% CI], 1.282-3.543) and no visualized pedal arch (SHR, 3.022; 95% CI, 1.553-5.883) compared with CPA. Pedal arch was important even if angiosome-targeted revascularization was achieved: Angiosome-directed revascularization in presence of CPA had a lower risk of major amputation (adjusted SHR, 0.463; 95% CI, 0.240-0.894) compared with angiosome-directed revascularization without CPA. In the subanalysis, among patients who underwent endovascular revascularization, CPA (SHR, 0.509; 95% CI, 0.286-0.905) and angiosome-targeted revascularization (SHR, 0.613; 95% CI, 0.394-0.956) were associated with a lower risk of major amputation.
Conclusions: Competing risk analysis showed that a patent pedal arch had significant impact on leg salvage and that the subset of patients undergoing endovascular procedure may most benefit of an angiosome-targeted revascularization.
Copyright © 2020. Published by Elsevier Inc.
Similar articles
-
Impact of angiosome- and nonangiosome-targeted peroneal bypass on limb salvage and healing in patients with chronic limb-threatening ischemia.J Vasc Surg. 2017 Nov;66(5):1479-1487. doi: 10.1016/j.jvs.2017.04.074. Epub 2017 Jul 26. J Vasc Surg. 2017. PMID: 28756043
-
Pedal arch patency and not direct-angiosome revascularization predicts outcomes of endovascular interventions in diabetic patients with critical limb ischemia.Int Angiol. 2017 Oct;36(5):438-444. doi: 10.23736/S0392-9590.17.03809-3. Epub 2017 May 24. Int Angiol. 2017. PMID: 28541016
-
Outcomes of angiosome and non-angiosome targeted revascularization in critical lower limb ischemia.J Vasc Surg. 2013 Jan;57(1):44-9. doi: 10.1016/j.jvs.2012.07.042. Epub 2012 Oct 9. J Vasc Surg. 2013. PMID: 23058724
-
In the Loop: Endovascular Pedal Arch Revascularization.Ann Vasc Surg. 2024 Oct;107:84-92. doi: 10.1016/j.avsg.2023.12.099. Epub 2024 Apr 4. Ann Vasc Surg. 2024. PMID: 38582203 Review.
-
Comparing the efficacy and safety of endovascular therapy versus surgical revascularization for critical limb-threatening ischemia: A systematic review and Meta-analysis.Prog Cardiovasc Dis. 2025 Jan-Feb;88:126-135. doi: 10.1016/j.pcad.2024.06.008. Epub 2024 Jul 7. Prog Cardiovasc Dis. 2025. PMID: 38981532
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials